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Abstract
Introduction:  Remission  is  the  ultimate  goal  of  the  treatment  of  rheumatoid  arthritis  (RA).
However,  the  diagnosis  of  remission  might  still  be  vague.  Musculoskeletal  ultrasound  (US)  seems
to effectively  assess  synovitis,  effusion  and  bone  damage.  Thus,  its  role  could  be  relevant  for
the diagnosis,  monitoring  or  detection  of  relapse  in  the  follow-up  of  RA  in  remission.  The  goal  of
this review  of  the  literature  was  to  clarify  the  added  value  of  ultrasonography  during  remission.
Methods:  A  systemic  search  of  the  literature  was  performed  on  Medline  and  Scopus.  The  follow-
ing key  words  were  used:  rheumatoid  arthritis,  remission,  US.  Fifty-six  papers  were  collected,
then after  an  in  depth  analysis,  twelve  articles  were  selected  for  analysis.
Results:  Twelve  papers  were  identiﬁed  that  assessed  remission  in  RA.  Remission  criteria  varied
from one  author  to  another.  The  number  of  joints  assessed  by  US  varied  from  six  to  44  with
the wrist  and  metacarpo-phalangeal  joints  of  the  dominant  hand  scanned  at  least.  Irrespective
of remission  criteria,  all  authors  demonstrated  that  US  detected  Doppler  positive  synovitis  in
patients in  clinical  remission.  Also,  power  Doppler  synovitis  predicted  structural  damage  and
future ﬂares  of  RA.
Conclusion:  US  seems  to  be  more  effective  than  a  clinical  exam.  True  remission  in  RA  must  be
deﬁned.  Moreover,  the  inclusion  of  this  technique  in  the  new  deﬁnition  of  remission  is  being
validated.
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n  the  past  few  decades,  the  rate  of  remission  in  rheumatoid
rthritis  (RA)  had  increased  thanks  to  the  intensive  prescrip-
ion  of  disease  modifying  antirheumatic  drugs  [1]  and  the
ntroduction  of  biotherapies  when  necessary  [2].  A  speciﬁc
trategy  of  treating  early  RA  adapted  to  each  patient  and
ncluding  close  follow-up,  called  ‘‘Treat  To  Target’’  is  now
eing  implemented  [3].  Indeed,  it  has  been  shown  that  soon
fter  the  onset  of  RA,  there  is  a  period  of  time  called  a  win-
ow  of  opportunity  when  effective  treatment  can  induce
emission  in  a  signiﬁcant  number  of  patients  [4].  Obtaining
emission  in  RA  is  our  ultimate  goal  because  this  is  the  only
ay  to  prevent  structural  progression  and  articular  damage.
everal  deﬁnitions  of  remission  have  been  established  and
ll  of  them  take  into  account  clinical  and  biological  criteria.
owever,  numerous  studies  have  shown  evidence  of  persis-
ent  infra-clinical  synovitis  on  imaging,  in  particular  with
usculoskeletal  ultrasound  (US)  [5—7].  Moreover,  muscu-
oskeletal  US  has  now  been  proposed  as  one  of  the  remission
riteria  for  monitoring  RA  [8].
The  goal  of  this  review  of  the  literature  was  to  assess  the
ole  of  US  in  evaluating  RA  in  remission,  to  determine  which
oints  should  be  assessed,  and  which  scores  should  be  used.
aterials and methods
e  performed  a  systematic  search  of  the  literature  from
005  to  2013  using  the  Medline  and  Scopus  databases  with
he  following  keywords:  rheumatoid  arthritis;  remission  and
ltrasound.  Fifty-six  papers  were  identiﬁed.  Only  articles
ublished  in  French  or  English  were  selected.  Seven  arti-
les  were  excluded  because  they  evaluated  US  on  vessels
nd  three  others  MRI.  Thirteen  articles  evaluated  active  RA.
linical  cases;  letters;  and  editorials  were  also  excluded.  A
otal  of  twelve  articles  that  met  our  criteria  were  selected
or  analysis.
A  summary  of  the  selected  articles  is  provided  in  Fig.  1.
esults
ur  review  of  the  literature  included  12  articles  evaluating
he  role  of  osteoarticular  US  in  patients  followed-up  for  RA
n  remission.  All  studies  were  prospective.  The  main  results
re  summarized  in  Table  1.
First,  we  looked  at  the  deﬁnitions  of  « remission  » that
ere  used  in  different  studies.  We  then  identiﬁed  the  dif-
erent  joints  and  scores  used  in  US.  Finally,  the  added  value
f  US  for  monitoring  remission  was  identiﬁed  in  each  study.
eﬁnition of remission
nclusion  criteria  varied  from  one  study  to  another.  In  4/12
rticles,  remission  was  based  on  the  physician’s  judgment
9—12].  However,  objective  composite  scores  to  evaluate
A  activity  showed  that  numerous  patients  were  not  in
emission.  The  different  scores  used  included  the  modiﬁed
merican  College  of  Rheumatology  (ACR)  criteria,  the  Dis-
ase  Activity  Score  of  28  joints  (DAS  28),  and/or  the  Simple
isease  Activity  Index  (SDAI)  (Appendix  1).  The  percentage
3
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eigure 1. Selection of articles.
f  patients  in  remission  according  to  these  different  scores
s  summarized  in  Table  2. When  ACR  or  DAS  28  criteria  were
sed,  between  76  and  54%  of  patients  were  in  remission.
hen  SDAI  criteria  were  used  (with  a  cutoff  of  3.3),  only  29
o  44%  were  in  remission.  The  duration  of  remission  accord-
ng  to  these  scores  varied  from  2  [13]  to  6  months  [14—17].
ltrasound assessment, number of joints
ested and scoring
he  physicians  assessing  joints  on  US  were  blinded  to  clin-
cal  and  biological  ﬁndings  in  all  the  articles  in  this  study.
ll  operators  used  B-mode  to  assess  synovial  hypertrophy
SH)  and  Power  Doppler  (PD)  to  assess  synovial  vasculariza-
ion.  The  OMERACT  2005  (Outcome  Measures  in  Rheumatoid
rthritis  Clinical  Trials)  [18]  deﬁnitions  were  used  to  deﬁne
-mode  and  PD  synovitis.
oint  scores
-mode  SH  and  PD  hypervascularization  were  determined
sing  a  semi-quantitative  score  in  all  studies  except  one.
hen  a  semi-quantitative  score  was  used,  a  grade  of  0  to was  assigned  to  each  joint  depending  on  the  extent  of  B-
ode  SH  and  then  these  scores  were  added  together.  Also,
 score  of  0  to  3  was  used  for  each  joint  depending  on  the
xtent  of  DP  synovial  vascularization  and  the  scores  were
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Table  1 The  added  value  of  ultrasonography  RA  remission  according  to  different  studies.
Author
Year
Population Remission  criteria Joints  scanned US  ﬁndings:
B-mode
synovitis
US ﬁndings:
PD synovitis
Clinically
healthy  joints
(number,  %)
PD infra-clinical
synovites
(number,  %)
Brown  et  al.,
2006  [9]
107  RA
remission
Physicians’
judgment
Period >  6  months
8 wrist  (4  sites)
MCP  2-5  of  the  dominant
hand
84.9%  60.4%  725.
86%
241.
33%
Wakeﬁeld
et  al.,  2007
[20]
10  early  RA DAS28  <  2.6
Period  >  6  months
42 shoulders,  elbows,  wrists,
MCP,  PIP,  knees,  ankles,  MTP
For  patients  in
remission:
50.7%
For  patients  in
remission:
15.2%
Not  speciﬁed Not  speciﬁed
Brown  et  al.,
2008  [10]
102  RA
remission
Physicians’
judgment
8 wrist  (4  joints)
MCP  2-5
Dominant  hand
84%  51%  378.
82%
56.
15%
Saleem  et  al.,
2009  [14]
100  RA
Remission
DAS28 ≤  2.6
Period  >  6  months
6 wrist
5 MCP
Dominant  hand
87%  46%  450.
75%
227.
50.5%
Sciré  et  al.,
2009  [19]
106  RA
43
remission
DAS ≤  1.6
Period  >  3  months
44 shoulders,  sterno  et
acromio-clavicular  joints,
elbows,  wrists,  MCP,  PIP,
knees,  ankles,  MTP
For patients  in
remission:  95%
For  patients  in
remission:  41%
Not  speciﬁed  Not  speciﬁed
RA: rheumatoid arthritis; DAS: Disease Activity Score; MCP: metacarpo-phalangeal; IPP: proximal interphalangeal; MTP: metatarso-phalangeal.
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Table  2  Percentage  of  patients  in  remission  according  to  the  different  RA  activity  scores  in  the  articles  with  physicians’
judgment  as  a  remission  criterion.
Authors  reference  Remission  according  to
physicians’  judgment
(number)
ACR  (%)  DAS28  <  2.6  (%)  SDAI  <  3.3  (%)
Remission  Active  Remission  Active  Remission  Active
Brown  et  al.,  [9]  107  55  45  57  43  —  —
Brown  et  al.,  [10]  102  —  —  56  44  —  —
Balsa  et  al.,  [11]  97  75  25  76  24  44  56
Naredo  et  al.,  [12]  76  —  
Table  3  Scoring  of  B-mode  synovitis.
Grade  0  or
Normal
Normal  joint:  no  synovial  thickness,  no
joint  effusion
Grade  1  or
Mild
Mild  synovial  hypertrophy  without  bulging
over  the  line  linking  the  tops  of  the  bones
Minimal  joint  effusion
Grade  2  or
Moderate
Moderate  synovial  hypertrophy  bulging
over  the  line  linking  the  tops  of  the
bones  but  not  extending  to  the  diaphysis
Minimal  joint  effusion
Grade  3  or
Severe
Severe  synovial  hypertrophy  bulging  over
the  line  with  extension  to  at  least  one
diaphysis
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PSigniﬁcant  joint  effusion
dded  together.  These  scores  are  presented  in  Table  3  for
H  and  Table  4  for  PD.
Besides  these  semi-quantitative  scores,  a  binary  score  (0
or  the  absence  of  synovitis  and  1  for  presence  of  synovitis)
as  used  in  one  study  [16].
ndividual  patient  scores
he  number  of  joints  evaluated  varied  from  six  [14]  to  forty-
our  [12,19].  The  scores  including  only  six  joints  assessed
hose  in  the  dominant  hand.  The  wrist  was  included  in  all
cores,  with  either  all  metacarpo-phalangeal  joints  (MCP)
14]  or  second  to  ﬁfth  MCP  joints  [9,10]. Certain  authors
ssessed  the  joints  of  the  feet  as  well  as  those  of  the  hands
11,12,19,20].  Large  joints,  such  as  the  shoulders,  elbows,
nees  and  ankles,  were  evaluated  in  two  articles  [12,19].
he  sterno-clavicular  and  acromio-clavicular  joints  and  hip
oints  were  each  included  in  one  study  [12,19].  The  different
cores  are  summarized  in  Table  5.
Table  4 Scoring  of  PD  synovitis.
Grade  0  No  PD  signal
Grade  1  3  isolated  spots  or  2  conﬂuent  spots  or  1
conﬂuent  spot  and  2  isolated  spots  of  signal
Grade  2  Vessel  signals  in  <  50%  of  the  areas  of  the
synovium
Grade  3  Vessel  signals  in  >  50%  of  the  area  of  the
synovium
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ltrasound results and ﬁndings
etection  of  infra-clinical  synovitis
n  all  the  articles  reviewed,  there  were  signiﬁcantly  more
ynovites  detected  in  B-mode  or  PD  than  the  number  of  clin-
cally  swollen  joints,  although  the  frequency  varied.  Indeed,
-mode  and  PD  synovitis  were  detected  in  50.7%  [20]  to  95%
f  cases  [19]  and  14.7%  [13]  to  57.4%  of  cases,  respectively
17]. Only  three  studies  reported  the  exact  number  of  clin-
cally  non  swollen  joints  and  the  percentage  of  those  with
S  synovitis  among  them  [9,10,14]. This  rate  varied  from
6  to  85%  for  US-SH  and  15  to  50.5%  for  PD  vasculariza-
ion.
redictive  value  for  relapse
he  predictive  value  of  US  for  future  relapse  was  studied  in  3
ut  of  12  studies  using  the  odds  ratio  (OR)  [13,16,19].  In  the
tudy  by  Peluso  et  al.  [16], the  OR  for  relapse  was  3.6  (95%
I:  1.4—9.0)  in  the  presence  of  a  Doppler  signal  and  based
n  an  evaluation  of  the  wrist,  second  and  third  MCP  joints
nd  PIP  joints  on  both  hands.  In  the  study  of  Foltz  et  al.
13], including  the  wrist,  second  to  ﬁfth  MCP  joints  and  PIP
oints  on  both  hands,  a  PD  signal  was  predictive  of  relapse
ithin  a  year  with  an  OR  of  6.5  (95%  CI:  2.0—20).  In  the  study
y  Sciré  et  al.  [19]  evaluating  44  joints,  a  Doppler  signal
redicted  the  risk  of  a  future  ﬂare  with  an  OR  of  13  (95%
I:  1.6—104).  The  predictive  value  of  B-mode  for  relapse
as  only  studied  in  two  articles  and  was  not  statistically
igniﬁcant  [13,19].
redictive  value  for  structural  progression
wo  studies  assessed  the  risk  of  structural  progression  in
atients  in  clinical  remission.  In  the  ﬁrst  article  by  Brown
t  al.  [10], including  one  hundred  and  two  patients,  eight
oints  (wrist  and  second  to  ﬁfth  MCP  joints  of  the  dominant
and)  were  assessed  in  each  patient.  B-mode  SH  was  pre-
ictive  of  progressive  structural  deterioration  with  an  OR
f  2.31  (95%  CI:  1.06—5.52)  and  the  presence  of  a  PD  sig-
al  was  also  associated  with  articular  damage  within  a  year
f  follow-up  with  an  OR  of  4  (95%  CI:  1.98—8.08).  The  sec-
nd  article  by  Foltz  et  al.  [13]  included  85  patients  in  whom
ourteen  joints  were  assessed  on  US.  Both  the  presence  of
H  and  a  Doppler  signal  were  predictive  of  structural  pro-
ression  with  an  OR  of  1.92  (95%  IC:  0.49—7.24)  and  of  1.4
95%  CI:  1.1—1.9),  respectively.
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Table  5  The  different  US  scores  adopted  by  the  authors.
Authors  reference  Number  of  joints  assessed  Joints  assessed
Saleem  et  al.,  [14]  6  Wrist
5  MCP
Dominant  hand
Brown  et  al.,  [9,10]  8  Wrist  (4  joints)
MCP  2-5
Dominant  hand
Peluso  et  al.,  [16]
Spinella  et  al.,  [17]
12  Wrists  (medio-  and  radiocarpal)
MCP  2-3  and  PIP  2-3
Bilateral
Foltz  et  al.,  [13]  14  Wrists
MCP  2-5
MTP  2-5
Bilateral
Saleem  et  al.,  [15]  18  Wrists
MCP  2-5
PIP  2-5
Bilateral
Sakellariou  et  al.,  [23]  22  Wrists
MCP
PIP
Bilateral
Wakeﬁeld  et  al.,  [20]
Balsa  et  al.,  [11]
42  Shoulders,  elbows,  wrists,  MCP,  PIP,  knees,  ankles,  MTP
Bilataral
Sciré  et  al.,  [19]  44  Shoulders,  sterno-  and  acromio-clavicular,  elbows,  wrists,
MCP,  PIP,  knees,  ankles,  MTP
Bilateral
Naredo  et  al.,  [12]  44  Wrists,  MCP,  PIP,  elbows,  shoulders,  hips,  knees,  ankles,
MTP
Bilateral
MCP: metacarpo-phalangeal; PIP: proximal interphalangeal; MTP: metatarso-phalangeal.
D
T
t
d
p
r
j
m
p
u
2
D
b
f
o
r
[
IComparison of  ultrasound abnormalities in the
different remission scores
Three  studies  [11,12,16]  compared  US  ﬁndings  in  relation  to
the  different  RA  remission  scores.
Balsa  et  al.  [11]  did  not  ﬁnd  any  signiﬁcant  difference
between  modiﬁed  ACR  and  DAS-28  criteria  for  the  number
of  active  joints,  on  B-mode  or  PD.  Indeed,  with  PD,  the
median  number  of  active  joints  was  2.07  ±  0.67  according  to
ACR  criteria  and  2.21  ±  0.79  according  to  DAS28  (P  =  0.49).
However,  when  using  SDAI  with  a  cutoff  of  <  3.3,  the  median
number  of  joints  with  synovitis  on  PD  was  signiﬁcantly
lower  than  with  ACR  and  DAS-28  criteria.  If  remission  was
deﬁned  as  « absence  of  PD  vascularized  joints  », the  sensi-
tivity  and  speciﬁcity  of  SDAI  were  57.4  (95%  CI:  44.2—69.7)
and  74.4  (95%  CI:  58.9—85.4)  respectively.  In  the  study  by
Naredo  et  al.  [12],  the  median  number  of  PD  hypervacular-
ized  joints  was  signiﬁcantly  greater  in  patients  in  remission
according  to  DAS-28  than  in  those  in  remission  according
to  SDAI  criteria.  Peluso  and  al.  [16]  showed  that  there  were
fewer  hypervascularized  synovites  using  DAS  remission  crite-
ria  (<  1.6)  than  with  ACR  remission  criteria  (PD:  36.5%  versus
83%).
b
p
Iiscussion
welve  articles  were  evaluated  in  this  review  of  the  litera-
ure.  They  all  assessed  the  role  of  US  for  detecting  persistent
isease  activity,  comparing  the  different  activity  scores  or
redicting  future  relapse  or  structural  progression  in  RA  in
emission.
To  deﬁne  remission,  most  studies  relied  solely  on  the
udgment  of  referring  physicians  [9—12]. However,  when
ore  objective  criteria  were  applied,  a  great  number  of
atients  were  no  longer  in  remission.  The  most  frequently
sed  scores  were  those  established  by  EULAR:  DAS  or  DAS-
8.  According  to  these  scores,  remission  is  deﬁned  by  a
AS  <  1.6  or  a  DAS28  <  2.6  [21]. These  scores  have  often
een  criticized  because  even  when  a  patient  fulﬁlled  criteria
or  remission,  the  presence  of  synovitis  may  still  be  found
n  US  [22]. Thus,  all  the  studies  that  used  DAS  or  DAS-28
emission  criteria  also  found  the  presence  of  synovitis  on  US
13—17,19,20,23]. The  SDAI  and  the  Clinical  Disease  Activity
ndex  (CDAI)  [24]  are  simpler  scores  that  have  been  shown  to
e  highly  effective,  would  be  easier  to  use  in  daily  clinical
ractice.  These  scores  do  not  require  special  calculators.
n  fact,  the  SDAI  is  the  numerical  sum  of  ﬁve  parameters:
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ender  joint  count  (TJC),  swollen  joint  count  (SJC)  (based
n  a  28-joint  assessment),  patient  global  assessment  (PGA),
lobal  physician  assessment  (GPA),  and  level  of  C-Protein
eactive  (CRP)  (Appendix  1).  RA  is  considered  to  be  in  remis-
ion  if  this  score  is  ≤  3.3.  CDAI  is  the  numerical  sum  of  four
arameters:  TJC  +  SJC  +  PGA  +  GPA.  A  score  of  ≤  2.8  conﬁrms
he  diagnosis  of  remission  (Appendix  1).  In  two  of  the  stud-
es  included  in  this  review  in  which  the  SDAI  score  was  used
o  deﬁne  remission,  fewer  B-mode  synovitis  were  detected
n  US  [11,12].  The  most  recent  criteria  for  remission  are
CR/EULAR  2011.  Remission  is  conﬁrmed  when  the  patient
ulﬁlls  all  of  the  following  criteria  at  any  time  of  the  dis-
ase:  TJC  ≤  1,  SJC  ≤  1,  CRP  ≤  1  mg/dL  and  PGA  ≤  1  (scale
rom  0—10)  [25].  This  score  was  only  used  in  one  study  of
akellariou  [23]  to  assess  remission.
A  semi-quantitative  score  was  used  in  B-mode  and  PD
o  each  joint  in  all  the  studies  reviewed.  The  score  used
as  very  similar  to  Szkudlarek’s,  which  is  the  most  widely
ccepted  because  of  its  simplicity  and  reproducibility.  Other
emi-quantitative  scores  are  available  such  as  Scheel’s  [26]
n  which  B-mode  SH  is  evaluated  by  measuring  the  height  of
he  perpendicular  line  joining  the  diaphyseal  cortex  to  the
pper  limit  of  the  synovial  surface,  with  a  limit  of  0.6  mm
o  distinguish  normal  from  pathological  effusion  [26].  This
uantitative  assessment  of  synovitis  might  be  more  effective
n  diagnosing  RA  remission.  Moreover,  precise  quantiﬁcation
f  the  Doppler  signal  can  be  obtained  by  counting  the  num-
er  of  colored  pixels  on  the  synovial  surface  [27].  None  of
he  studies  evaluated  used  this  method.
The  scores  used  in  the  articles  in  this  study  included
n  evaluation  between  6  and  44  joints.  The  wrist  and  MCP
oints  of  the  dominant  hand  were  included  in  all  scores.
xploration  of  large  joints  and  the  feet  was  rare.  Naredo
t  al.  [12]  compared  several  US  scores  and  showed  that  the
core  including  the  bilateral  assessment  of  the  wrists,  sec-
nd  to  ﬁfth  MCP  joints,  ankles  and  MTP  joints  seemed  to
ave  the  strongest  correlation  with  the  score  including  44
oints.  In  a  review  of  the  literature  by  Ten  Cate  and  al.
28],  a  minimal  score  including  the  wrists,  MCP  and  MTP
oints  was  necessary  to  evaluate  active  RA.  However,  for
A  in  remission,  assessment  of  the  wrist  and  the  MCP  joints
f  the  dominant  hand  was  enough.  Assessing  only  6  joints
resents  a  risk  of  ignoring  other  active  joints,  while  evalu-
ting  44  joints  would  be  too  time-consuming  for  daily  clinical
ractice.  A  standardized  US  score  that  must  be  validated  by
xpert  medical  societies  is  therefore  essential.  This  is  the
oal  of  the  Targeted  Ultrasound  Initiative  (TUI),  a  group  of
heumatologists  and  ultrasound  specialists  whose  purpose  is
o  establish  new  remission  criteria  that  include  US  [29].  In
ll  articles  included  in  our  review,  whatever  the  remission
riteria  used  and  whether  they  were  subjective  or  objec-
ive,  persistent  synovitis,  even  vascularized,  were  detected
n  US.  This  could  be  because  a  patient  could  fulﬁll  remis-
ion  criteria  based  on  composite  scores  of  RA  activity  (ACR,
AS,  DAS28,  SDAI),  but  still  have  a  clinically  swollen  joint.
owever,  Brown  et  al.  and  Saleem  et  al.  [9,10,14]  selected
atients  with  no  clinically  swollen  joints  and,  even  in  these
ases,  infra-clinical  vascularized  synovitis  were  detected  on
D  in  15  to  50%  of  the  cases.  The  detection  of  infra-clinical
ynovitis  in  patients  in  remission  could  be  very  important  for
he  prognostic  of  RA.  Indeed,  persistent  infra-clinical  synovi-
is  has  been  shown  to  be  predictive  of  a  future  ﬂare  and
D
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rogressive  structural  deterioration  [10,13,16].  The  esti-
ated  risk  of  joint  deterioration  at  3  to  5  years  was  between
9  and  54%  in  patients  in  remission  [30].  Whatever  the
emission  criteria  used,  the  frequency  of  synovitis  varied
onsiderably  in  the  studies  in  this  review  from  50  to  95%
ith  B-mode  US,  and  15  to  60%  for  PD.  These  differences
re  probably  due  to  the  different  methodologies  in  these
tudies.  First,  the  number  of  patients  in  remission  who  were
ncluded  differed  from  a  study  to  another  (from  10  to  166
atients).  Remission  criteria  also  differed  and  in  some  arti-
les,  it  was  only  based  on  the  physician’s  judgment  therefore
ncluding  patients  with  active  PA  and  creating  a  bias  in  US
esults.  Finally,  these  differences  could  mainly  be  due  to  the
umber  of  joints  evaluated  (from  6  to  44).
In  this  review  of  the  literature,  only  three  authors  com-
ared  US  results  among  the  different  RA  remission  scores.
here  was  no  signiﬁcant  difference  in  the  number  of  syn-
vites  based  on  B-mode  or  PD  when  a  patient  was  in
emission  using  ACR  or  DAS  criteria.  On  the  other  hand,
ewer  synovites  were  detected  on  US  in  patients  with  RA
n  remission  based  on  the  SDAI  score  with  a  limit  of  ≤  3.3,
P  =  0.006)  than  with  the  DAS28.  Thus,  the  SDAI  score  seems
o  have  the  strongest  correlation  with  remission.  Neverthe-
ess,  despite  the  use  of  these  scores,  infra-clinical  synovitis
an  still  be  present  [31].  Thus,  US  seems  to  be  the  only
eliable  technique  to  deﬁne  remission.
onclusion
he  main  goal  in  the  treatment  of  RA  is  to  achieve  remis-
ion  and  to  prevent  structural  damage,  which  is  a  major
ource  of  future  disability.  Several  scores  are  available  to
eﬁne  remission.  According  to  this  review  of  the  literature
n  RA  in  remission  and  despite  the  heterogeneity  of  articles
ncluded,  US  synovitis  was  present  in  patients  in  remission
hatever  the  score  used.  US  activity  was  found  to  be  at
east  36%  with  B-mode  and  15%  with  PD  depending  on  the
tudy.  Moreover,  persistent  synovitis  was  predictive  of  pos-
ible  relapse  and  joint  deterioration.  Ideally  all  joints  should
e  evaluated  to  assess  RA  activity.  However,  in  daily  clini-
al  practice,  this  would  be  tedious  and  time-consuming.  To
ate,  there  is  no  validated  score  that  precisely  deﬁnes  the
oints  to  be  explored.  However,  a  good  correlation  has  been
ound  between  evaluation  of  the  wrist  and  MCP  joints  of
he  dominant  hand  and  RA  activity  on  remission.  The  same
ercentage  of  cases  of  infra-clinical  synovitis  was  found  in
atients  who  were  considered  to  be  in  remission  on  ACR
riteria  and  the  DAS  or  DAS28  scores,  while  fewer  infra-
linical  synovites  were  detected  in  those  evaluated  by  the
DAI  score,  which  therefore  has  a stronger  correlation  with
emission.  Finally,  the  conﬁrmation  of  remission  by  US  seems
ecessary  to  determine  the  therapeutic  strategy,  avoid
elapse  and  especially  future  structural  progression.  While
aiting  for  new  criteria  of  RA  in  remission,  US  should  be
erformed  more  frequently  in  daily  practice  and  repeated
f  necessary.isclosure of interest
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Appendix 1. Tables A—C DAS 28: DAS 28 is a composite score of RA activity developed by
EULAR.  Twenty-eight speciﬁc joints are assessed: ten metacarpo-phalangeal joints, eight
proximal  interphalangeal joints of the hands, two interphalangeal joints of the thumbs,
two  wrists, two elbows, twho shoulders and two knees. The score includes TJC and SJC
on  palpation, the VS and PGA results. It is calculated using the following formula: DAS
28  = [0,56 ×√(TJC)] ± [0,28 ×√(SJC)] ± [0,7 × Ln(VS)] ± [0,014 × (PGA)]. The level of
RA  activity according to this score is summarized in Table A.
Table  A  Different  levels  of  RA  activity  according  to  DAS  28.
DAS  28  value  ≥  5.1  3.2  ≤  DAS  28  ≤  5.1  2.6  ≤  DAS  28  ≤  3.2  ≤  2.6
Level  of  activity  High  Moderate  Low  Remission
Clinical Disease Activity Index (CDAI): CDAI is the numerical sum of four parameters: TJC + SJC (28 joints assessed) + PGA + PGA. The
different levels of RA activity according to CDAI are summarized in Table B.
Table  B  Different  levels  of  RA  activity  according  to  CDAI.
CDAI  value  ≥  20  10  ≤  CDAI  ≤  20  ≤  10  ≤  2.8
Level  of  activity  High  Moderate  Low  Remission
Simple Disease Activity Index (SDAI): is the numerical sum of ﬁve parameters: TJC + SJC (28 joints assessed) + PGA + GPA + CRP. The different
levels of RA activity according to SDAI are summarized in Table C.
Table  C  Different  levels  of  RA  activity  according  to  SDAI.
SDAI  value  ≥  26  11  ≤  SDAI  ≤  26  ≤  11  ≤  3.3
Level  of  activity  High  Moderate  Low  Remission
New ACR/EULAR criteria proposed in 2011: are particularly used in clincal trials. Remission is deﬁned either by SDAI ≤ 3.3 or the following
Boolean criteria: TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/L, et PGA ≤ 10.
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